Satralizumab
Modify Date: 2024-01-14 12:42:35
Satralizumab structure
|
Common Name | Satralizumab | ||
|---|---|---|---|---|
| CAS Number | 1535963-91-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SatralizumabSatralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2]. |
| Name | Satralizumab |
|---|
| Description | Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IL-6 |
| In Vivo | Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus[1]. Animal Model: Rattus norvegicus (forty, male, 10-week-old, four equal groups)[1] Dosage: 120 mg Administration: Subcutaneously, once every 2 weeks, for 4 weeks Result: Prevented dTAA (descending thoracic aorta aneurysm) formation and progression. |
| References |
| No Any Chemical & Physical Properties |